Abstract
The aim of the present study was to investigate the optimum composition of Polycan (β-glucan complex) and calcium lactate-gluconate (CaLG) that exhibited the most beneficial effects in ovariectomy (OVX)-induced osteoporotic rats. Polycan and CaLG single formulas (100 mg/kg each), and three doses (50, 100 and 200 mg/kg) of three mixed formulas [polycan:CaLG (PCLG)=1:99, 5:95 and 10:90] were orally administered once a day for 84 days. The effects of the test materials were compared with those of a risedronate sodium-treated group. OVX resulted in an increase in body weight, decreased bone formation, elevated serum osteocalcin levels and urine deoxypyridinoline/creatinine ratio, as well as decreased serum bone-specific alkaline phosphatase levels, femur indices, bone mineral content, bone mineral density and failure load. However, these OVX-induced osteoporotic changes markedly decreased following the administration of the test materials. Continuous oral treatment of Polycan or CaLG single formulas and the PCLG mixed formulas preserved bone mass and strength. The PCLG 10:90 mixed formula exhibited the most favorable synergistic antiosteoporotic effects in the OVX-induced osteoporotic rats as compared with equal doses of the Polycan or CaLG single formulas.
Highlights
Osteoporosis is a metabolic bone disease resulting from a disturbance of normal bone remodeling that shifts the balance to bone resorption over bone formation, causing bone loss and fractures [1]
Significant increases (P
The BW of all the ovariectomized rats significantly increased during the administration of test material when compared with the sham control rats
Summary
Osteoporosis is a metabolic bone disease resulting from a disturbance of normal bone remodeling that shifts the balance to bone resorption over bone formation, causing bone loss and fractures [1]. Numerous attempts to develop novel agents capable of preventing and/or treating bone diseases have been investigated [3]. Antiresorptive agents are extensively used, more highly efficacious resorptive inhibitors with excellent safety and efficacy are required. Anabolic agents that stimulate bone formation are less well investigated in comparison to antiresorptive agents [4]. With advances in the understanding of osteoblast differentiation and bone formation, continuous trials to develop anabolic agents have been performed [5,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
